FDA approves Eisai, Biogen’s Leqembi Iqlik subcutaneous initiation dose for early Alzheimer’s disease
BIIB•US launch planned for late August 2026
Eisai said the US launch is planned for late August 2026.
Biogen co-commercializes lecanemab with Eisai.
FDA clears once-weekly subcutaneous initiation dose
The FDA has cleared Eisai’s once-weekly LEQEMBI IQLIK subcutaneous injection as an initiation dose for early Alzheimer’s disease.
The product is intended to let patients start treatment with an at-home autoinjector instead of intravenous infusions.
